Linden Thomas Advisory Services LLC Has $1.10 Million Position in Bruker Co. (NASDAQ:BRKR)

Linden Thomas Advisory Services LLC lowered its stake in shares of Bruker Co. (NASDAQ:BRKR) by 2.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 18,696 shares of the medical research company’s stock after selling 535 shares during the period. Linden Thomas Advisory Services LLC’s holdings in Bruker were worth $1,096,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in BRKR. Wealth Enhancement Advisory Services LLC raised its position in Bruker by 1.4% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 13,287 shares of the medical research company’s stock worth $779,000 after purchasing an additional 177 shares in the last quarter. UMB Bank n.a. increased its holdings in shares of Bruker by 37.5% in the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 248 shares in the last quarter. US Bancorp DE increased its holdings in shares of Bruker by 2.1% in the third quarter. US Bancorp DE now owns 12,700 shares of the medical research company’s stock valued at $877,000 after purchasing an additional 260 shares in the last quarter. Coldstream Capital Management Inc. boosted its stake in Bruker by 7.3% in the third quarter. Coldstream Capital Management Inc. now owns 4,553 shares of the medical research company’s stock valued at $312,000 after acquiring an additional 308 shares during the last quarter. Finally, National Bank of Canada FI boosted its stake in Bruker by 0.3% in the third quarter. National Bank of Canada FI now owns 94,867 shares of the medical research company’s stock valued at $6,551,000 after acquiring an additional 318 shares during the last quarter. Institutional investors and hedge funds own 79.52% of the company’s stock.

Insider Transactions at Bruker

In related news, CEO Frank H. Laukien bought 100,000 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The shares were acquired at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the completion of the purchase, the chief executive officer now directly owns 38,439,563 shares in the company, valued at $1,927,359,688.82. The trade was a 0.26 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 28.30% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on BRKR shares. Guggenheim reissued a “buy” rating on shares of Bruker in a research report on Friday, January 17th. TD Cowen reduced their price target on shares of Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research report on Wednesday, November 6th. UBS Group assumed coverage on shares of Bruker in a research report on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 price objective on the stock. Barclays cut their price objective on shares of Bruker from $75.00 to $69.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th. Finally, Bank of America boosted their price objective on shares of Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, December 13th. Six equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $74.45.

Bruker Price Performance

BRKR stock opened at $57.29 on Friday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.66 and a quick ratio of 0.73. Bruker Co. has a 1 year low of $48.07 and a 1 year high of $94.86. The company has a 50 day simple moving average of $58.16 and a 200 day simple moving average of $61.55. The stock has a market cap of $8.69 billion, a price-to-earnings ratio of 27.54, a P/E/G ratio of 3.51 and a beta of 1.17.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.61 by ($0.01). Bruker had a net margin of 9.41% and a return on equity of 21.52%. The business had revenue of $864.40 million during the quarter, compared to analyst estimates of $866.46 million. During the same quarter last year, the company posted $0.74 earnings per share. The company’s revenue was up 16.4% compared to the same quarter last year. Research analysts anticipate that Bruker Co. will post 2.4 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Stockholders of record on Monday, December 2nd were given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.35%. The ex-dividend date of this dividend was Monday, December 2nd. Bruker’s dividend payout ratio (DPR) is presently 9.62%.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.